Safety and tolerability of psilocybin-assisted physiotherapy in healthy volunteers

This interventional trial (n=12) aims to assess the safety and tolerability of psilocybin-assisted physiotherapy (5-20mg) in healthy volunteers.

The study seeks to understand the feasibility of performing basic movement tasks prescribed by a physiotherapist after the administration of psilocybin. 12 healthy participants will receive three separate doses of psilocybin (5mg, 10mg, 15mg, or 20mg) according to a Williams study design, with each dose taken at least one week apart.

The trial is approved by the Austin Health Human Research Ethics Committee. The primary outcome measures include the participants’ ability to complete movement tasks and the occurrence of adverse events following each dose of psilocybin. Secondary outcomes include participants’ experiences of the intervention, performance on a computer task assessing sense of motor agency, and changes in brain functional connectivity measured via resting state fMRI scans.

The study is conducted by Prof Richard Kanaan and funded by Austin Health, the Melbourne School of Psychological Sciences (University of Melbourne), and the Usona Institute. Recruitment is ongoing in Australia, with a target of 12 participants. Data sharing for individual participant data (IPD) is not planned.

Topic Healthy Subjects
Compound Psilocybin
Country Australia
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Usona Institute
The Usona Institute was founded by Bill Linton and Malynn Utzinger. Currently, 18 people are associated with it. The institute is a non-profit that sponsors psilocybin research (and is funded by sponsors/philanthropists).

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.